NASDAQ:CNMDCONMED Stock Price, Forecast & News

$81.76

+4.83 (+6.28 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$79.38

Now: $81.76▼

$84.05

50-Day Range

$63.63

MA: $69.95▼

$76.93

52-Week Range

$37.66

Now: $81.76▼

$116.81

Volume425,985 shs

Average Volume450,232 shs

Market Capitalization$2.33 billion

P/E Ratio86.06

Dividend Yield1.04%

Beta0.56

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and VCARE uterine manipulator for enhancing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers endoscopic technologies offering, including diagnostic and therapeutic products for use in gastroenterology procedures; cardiology and critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company markets its products directly to surgeons, hospitals, surgery centers, group purchasing organizations, integrated delivery networks, and other customers, as well as through medical specialty distributors. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
CONMED has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $97.17, CONMED has a potential upside of 18.8% from its current price of $81.76.
Amount of Analyst Coverage
CONMED has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
CONMED has received 401 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
CONMED has received 371 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
CONMED has received 51.94% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote “Outperform” if you believe CNMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CNMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Leadership
CONMED is a leading dividend payer. It pays a dividend yield of 1.04%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
CONMED does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of CONMED is 30.30 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, CONMED will have a dividend payout ratio of 22.28 % next year. This indicates that CONMED will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CONMED insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.38% of the stock of CONMED is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for CONMED are expected to grow by 15.81% in the coming year, from $3.10 to $3.59 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CONMED is 86.06, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 17.17.
Price to Earnings Ratio vs. Sector
The P/E ratio of CONMED is 86.06, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.91.
Price to Earnings Growth Ratio
CONMED has a PEG Ratio of 2.18. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
CONMED has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.98 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Electromedical equipment

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNASDAQ:CNMD

Previous Symbol

CUSIP20741010

CIK816956

Webwww.conmed.com

Phone315-797-8375

Debt

Debt-to-Equity Ratio1.11

Current Ratio2.48

Quick Ratio1.40

Price-To-Earnings

Trailing P/E Ratio86.06

Forward P/E Ratio26.37

P/E Growth2.18

Sales & Book Value

Annual Sales$955.10 million

Price / Sales2.44

Cash Flow$3.57 per share

Price / Cash Flow22.89

Book Value$23.54 per share

Price / Book3.47

Profitability

EPS (Most Recent Fiscal Year)$2.64

Net Income$28.62 million

Net Margins3.00%

Return on Equity11.18%

Return on Assets4.43%

Miscellaneous

Employees3,100

Outstanding Shares28,528,000

Market Cap$2.33 billion

Next Earnings Date7/29/2020 (Estimated)

OptionableOptionable

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

CONMED (NASDAQ:CNMD) Frequently Asked Questions

How has CONMED's stock been impacted by COVID-19 (Coronavirus)?

CONMED's stock was trading at $78.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CNMD stock has increased by 3.8% and is now trading at $81.76. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CONMED?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CONMED.

When is CONMED's next earnings date?

CONMED is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for CONMED.

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) issued its quarterly earnings results on Wednesday, April, 29th. The medical technology company reported $0.51 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.44 by $0.07. The medical technology company earned $214 million during the quarter, compared to the consensus estimate of $214.85 million. CONMED had a net margin of 3.00% and a return on equity of 11.18%. CONMED's revenue for the quarter was down 2.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.57 EPS. View CONMED's earnings history.

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED announced a quarterly dividend on Friday, May 22nd. Shareholders of record on Monday, June 15th will be given a dividend of $0.20 per share on Monday, July 6th. This represents a $0.80 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend is Friday, June 12th. View CONMED's dividend history.

What price target have analysts set for CNMD?

7 brokerages have issued 12-month price objectives for CONMED's stock. Their forecasts range from $76.00 to $115.00. On average, they anticipate CONMED's share price to reach $97.17 in the next year. This suggests a possible upside of 18.8% from the stock's current price. View analysts' price targets for CONMED.

Has CONMED been receiving favorable news coverage?

Press coverage about CNMD stock has trended neutral recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CONMED earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news stories about the medical technology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutCONMED.

Who are some of CONMED's key competitors?

Some companies that are related to CONMED include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Masimo (MASI). View all competitors.

What other stocks do shareholders of CONMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CONMED investors own include AbbVie (ABBV), Bausch Health Companies (BHC), Gilead Sciences (GILD), Incyte (INCY), Moody's (MCO), Neurocrine Biosciences (NBIX), AT&T (T), Verizon Communications (VZ), Zoetis (ZTS) and Align Technology (ALGN).

Who are CONMED's key executives?

CONMED's management team includes the following people:

Mr. Curt R. Hartman, CEO, Pres & Director (Age 55)
Mr. Todd W. Garner, Exec. VP & CFO (Age 50)
Mr. Patrick J. Beyer, Pres of CONMED International (Age 53)
Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 44)
Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 44)

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

Who are CONMED's major shareholders?

CONMED's stock is owned by many different retail and institutional investors. Top institutional investors include Capital Research Global Investors (5.08%), Champlain Investment Partners LLC (4.48%), State Street Corp (3.32%), Principal Financial Group Inc. (3.28%), Loomis Sayles & Co. L P (1.64%) and Eagle Asset Management Inc. (1.54%). Company insiders that own CONMED stock include Daniel Jonas, Dirk Kuyper, Heather L Cohen, John Jed Kennedy, John L Workman, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III and Terence M Berge. View institutional ownership trends for CONMED.

Which institutional investors are selling CONMED stock?

CNMD stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Federated Hermes Inc., Columbus Circle Investors, JPMorgan Chase & Co., Oak Ridge Investments LLC, Bank of New York Mellon Corp, Parametric Portfolio Associates LLC, and UBS Group AG. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Dirk Kuyper, John Jed Kennedy, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III, and Terence M Berge. View insider buying and selling activity for CONMED.

Which institutional investors are buying CONMED stock?

CNMD stock was purchased by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Deutsche Bank AG, Rock Springs Capital Management LP, Champlain Investment Partners LLC, AXA, Wells Fargo & Company MN, Ranger Investment Management L.P., and Grantham Mayo Van Otterloo & Co. LLC. Company insiders that have bought CONMED stock in the last two years include Heather L Cohen, and John L Workman. View insider buying and selling activity for CONMED.

How do I buy shares of CONMED?

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $81.76.

How big of a company is CONMED?

CONMED has a market capitalization of $2.33 billion and generates $955.10 million in revenue each year. The medical technology company earns $28.62 million in net income (profit) each year or $2.64 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

What is CONMED's official website?

The official website for CONMED is www.conmed.com.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.

This page was last updated on 6/6/2020 by MarketBeat.com Staff